TransCode Therapeutics Reports Positive Phase 1a Results for TTX-MC138, Advancing Toward Phase 2a

TransCode Therapeutics (NASDAQ: RNAZ) reported additional positive results from its Phase 1a dose-escalation trial of TTX-MC138, an investigational microRNA-10b inhibitor for advanced cancer. The study met its primary safety endpoint, with no dose-limiting toxicities observed across 16 patients who received a total of 86 doses. The company highlighted durable disease stabilization in multiple patients, including three participants who remain on treatment after 14, 16, and 21 cycles, supporting the advancement of TTX-MC138 into Phase 2a clinical development.

Among 14 evaluable patients, nine (64%) achieved stable disease lasting at least six months based on RECIST criteria. TransCode also reported pharmacokinetic data demonstrating drug bioavailability consistent with preclinical findings. Notably, a metastatic thyroid cancer patient experienced a significant decline in thyroglobulin levels and has maintained stable disease for 12 months. The company stated that these results support the selection of a recommended Phase 2a dose of 4.8 mg/kg and provide a rationale for continued clinical development in patients with limited treatment options.

TTX-MC138 is designed to treat metastatic tumors that overexpress microRNA-10b, a biomarker of metastasis. TransCode Therapeutics is a clinical-stage company pioneering immuno-oncology and RNA therapeutic treatments for high-risk and advanced cancers. The company also has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells.

For more information, the full press release is available at https://ibn.fm/4WzoX. Latest news and updates relating to RNAZ are available in the company’s newsroom at https://ibn.fm/RNAZ.